Table 1.
Clinical and demographic characteristics among all and COVID‐19 rituximab‐treated pwMS compared to KPSC’s non‐MS population.
| Total population | COVID‐19 population | |||||
|---|---|---|---|---|---|---|
| RTX‐MS | non‐MS | p‐value | RTX‐MS | non‐MS | p‐value | |
| n = 1895 | n = 4,813,365 | n = 24 | n = 65,520 | |||
| Age, y, mean (SD) | 44.5 (12.3) | 38.9 (22.2) | <0.0001 | 42.4 (10.1) | 40.9 (17.4) | 0.4799 |
| Sex, females, n (%) | 1364 (72.0) | 2,470,408 (51.3) | <0.0001 | 15 (62.5) | 34,611 (52.8) | 0.6368 |
| Race/ethnicity, n (%) | <0.0001 | 0.0210 | ||||
| White | 867 (45.8) | 1,442,350 (30.0) | 7 (29.2) | 10,132 (15.5) | ||
| Black | 293 (15.5) | 362,922 (7.5) | 4 (16.7) | 3736 (5.7) | ||
| Hispanic | 598 (31.6) | 1,927,709 (40.0) | 13 (54.2) | 43,274 (66.0) | ||
| Asian/Pacific | 51 (2.7) | 524,788 (10.9) | 0 (0) | 3976 (6.1) | ||
| Other | 86 (4.5) | 555,596 (11.5) | 0 (0) | 4402 (6.7) | ||
| Charlson comorbidity index, mean (SD) | 0.6 (1.2) | 0.5 (1.2) | <0.0001 | 1.2 (2.0) | 0.5 (1.3) | 0.0138 |
| Elixhauser comorbidity index, mean (SD) | 2.3 (1.7) | 0.9 (1.6) | <0.0001 | 3.0 (2.7) | 1.0 (1.6) | <0.0001 |
| Maximum COVID‐19 severity, n (%) | ||||||
| Mild (not hospitalized) | — | — | 16 (66.7) | 60,799 (92.8) | 0.0002 | |
| Moderate (hospitalized) | — | — | 8 (33.3) | 3799 (5.8) | <0.0001 | |
| Death | — | — | 0 (0) | 922 (1.4) | 1.0 | |
| Hospital stay duration, mean (SD) | 6.9 (3.5) | 11.0 (11.2) | 0.4115 | |||
Abbreviations: MS, multiple sclerosis; pwMS, persons with multiple sclerosis; RTX, rituximab; SD, standard deviation; y, years.